1 / 14

MCQ – I V INDUCTION AGENTS

MCQ – I V INDUCTION AGENTS. For intravenous anaesthetic agents: FFTTT

chester-dunlap
Download Presentation

MCQ – I V INDUCTION AGENTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MCQ – I V INDUCTION AGENTS

  2. For intravenous anaesthetic agents: • FFTTT a) the end point of induction of anaesthesia is loss of the eyelash reflex b) the clearance is their rate of excretion c) lower doses will be required for induction in hypovolaemic patients d) the effects on the CNS. depend on their degree of ionisation e) their non-protein bound fraction increase in liver and renal diseases

  3. Factors which affect the peak effect of intravenous anaesthetics include: • TFFTT a) dose administeredb) volume of distributionc) hepatic clearanced) rate of injectione) cardiac output

  4. Midazolam: • TTTTT a) has a half-life of less than 2 hours b) is water soluble at a pH 4 c) has an active metabolite d) can have a prolonged effect if given with erythromycin e) can be given by the intranasal route

  5. Midazolam: • TTFTT a) is an anticonvulsant b) is lipid soluble at physiological pH c) has no active metabolites d) has an elimination half-life of 2-4 hours e) can be administered as nasal drops for premedication  

  6. Ketamine: • TTTFT a) raises the plasma noradrenaline level b) can cause unpleasant side-effects in adults for 24 hours after administration c) is a depressant to denervated cardiac muscle d) produces a loss of consciousness in one arm-brain circulation time e) is a bronchdilator

  7. Ketamine: • FFFFF a) is an imidazole derivativeb) has also antanalgesic effectc) is contraindicated rectallyd) has no active metabolitese) probably has no effect on intracranial pressure

  8. Ketamine: • TFTTT a) has marked analgesic properties mediated by its binding to NMDA receptors b) causes a fall in cardiac output and a rise in heart rate c) is contraindicated in patients with raised intracerebral pressure d) has active metabolites e) causes postoperative dreaming and hallucinations which are less frequent in children

  9. S(+) ketamine compared with R(-) ketamine: • TTTTT a) is 3-4 times more potent b) is associated with less incidence of emergence reaction c) is a better analgesic d) has a faster recovery e) has a higher affinity for NMDA receptors

  10. Methohexitone: • TTTFF a) is an oxybarbiturateb) may cause pain on injectionc) is a methylated hexobarbitoned) is safer in asthma than thiopentonee) has a shorter half life than propofol

  11. Propofol: • FTTFT a) has a pH of 7.0 b) is insoluble in water c) is twice as potent as thiopentone d) can be given as an infusion because its terminal half-life is less than 30 minutese) may change the colour of urine due to propofol glucuronide  

  12. Propofol: • TTTTT a) is insoluble in water b) is bound to albumin up to 97-98% c) reduces sodium channel opening times in neuronal membranes d) is isotonic e) does not cause tachycardia

  13. Thiopentone causes a decrease in BP by :A. Direct decrease in myocardial contractilityB. Fall in systemic vascular resistanceC. Decrease in venous tone • Thiopentone:A. Is the sulphur analogue of phenobarbitoneB. Has higher protein binding than its oxy analogueC. ? 6% sodium bicarbonateD. Isotonic at 2.5% concentration

  14. Methohexitone:A. Has a molecular weight of 285B. Has a melting point of 158 degreesC. A 2.5% solution is isotonicD. Is yellow

More Related